Pancreatic adenocarcinoma (also called pancreatic ductal carcinoma) is the most common type of pancreatic cancer, originating in the exocrine cells of the pancreatic duct. It accounts for 90% to 95% of pancreatic cancer cases (American Cancer Society [ACS], 2024; Puckett and Garfield, 2024). Diagnosis of pancreatic adenocarcinoma is challenging because it is generally silent in its early stages. Any clinical symptoms are relatively nonspecific, and are similar to those of pancreatitis. As a result, most cases of pancreatic adenocarcinoma are not diagnosed until advanced stages, and the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis (Bugazia et al., 2024). The 5-year survival rate is very low, ranging from 5% to 15% (ACS, 2024; Puckett and Garfield, 2024). Pancreatic cancer is the third leading cause of cancer deaths in the United States. It is estimated that 67,440 new U.S. cases will be diagnosed, and 51,980 patients will die from pancreatic cancer in 2025 (National Cancer Institute [NCI], 2025).